At #SITC2024, we presented initial clinical pharmacodynamic data from our ST316 Phase 1 study, demonstrating that ST316 dramatically depletes immunosuppressive cells from peripheral blood of patients. These findings were supported by non-clinical studies, where we were pleased to see that treatment with ST316 and PD-1 checkpoint inhibitors had positive effects on tumor outcomes and immune activation. Learn more here: https://lnkd.in/g2tKj76G #SITC2024 #Oncology #CRC #Colorectalcancer #DrugDevelopment
Sapience Therapeutics, Inc.’s Post
More Relevant Posts
-
At #ESMO24, we unveiled results from a new study showing how PARP inhibitors (PARPi) can benefit patients with ovarian, pancreatic, prostate, and triple-negative breast cancers. Using Cellworks personalized therapy biosimulation, we identified homologous recombination deficiency(HRD) beyond BRCA mutation status, providing more comprehensive predictions of patient response to PARPi therapies. A special thank you to Dr. Daniel Palmer, Principal Investigator of the study, for his work with us and advancing personalized therapy for cancer patients. You can read details about the study here - https://lnkd.in/gDeawZj7 #ESMO24 #PersonalizedMedicine #Biosimulation #Oncology #Cellworks
-
-
Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive Advanced/Metastatic NSCLC 📢 #MedicalOncology #CancerNews #Oncology #Cancer
-
CROWN is a phase 3 clinical trial evaluating progression free survival with the use of loratinib in patients with advanced ALK+ NSCLC. #LungCancer #oncology https://lnkd.in/gWGWE-YV
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
onclive.com
-
CROWN is a phase 3 clinical trial evaluating progression free survival with the use of loratinib in patients with advanced ALK+ NSCLC. #LungCancer #oncology https://lnkd.in/gWGWE-YV
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
onclive.com
-
#BreakingNews: The first patient has been enrolled in our Phase 2 expansion study evaluating ST316, our first-in-class antagonist of β-catenin (NCT05848739). ST316 selectively shuts down the Wnt/β-catenin signaling pathway in tumor cells but not in normal cells, allowing for anti-cancer activity without the toxicity related to broad inhibition of this pathway. The Wnt/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in our Phase 2 expansion study. Click here to learn more: https://lnkd.in/gyqWuTMx #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment
-
-
Systematic review and meta-analysis (DOI: 10.3389/fimmu.2024.1339757) involving 1,074 patients examines neoadjuvant immunotherapy in gastric and gastroesophageal junction tumors. Results indicate a good safety profile and effectiveness, with a substantial rate of pathological complete remission and R0 resection. Continued multicenter trials are essential to fully ascertain the benefits of immunotherapy combinations in these cancers. #OncologyResearch #TreatmentEfficacy #PatientOutcomes #ImmunotherapyAdvancements
-
-
Ivonescimab, a humanized IgG1 bispecific anti-PD-1/VEGF antibody, is currently being studied for its safety and efficacy in patients with extensive-stage small cell lung cancer (ES-SCLC). This study aims to assess the safety and tolerance of ivonescimab when combined with etoposide and carboplatin as a first-line treatment. Stephen Liu Jarushka Naidoo Biagio Ricciuti For more information, visit: https://lnkd.in/eTz95b6i #Ivonescimab #CancerTreatment #OncoDaily #Oncology #Cancer #Health #Medicine
-
-
Dive into the latest advances in the utility of #PIK3CA/#TP53 mutation for stratifying patients with HR+/HER2- metastatic breast cancer for optimal first-line therapy. Then swing by Booth #12139 for additional insights and networking. FRESH BAKED cookies will be served! Dr. Federico Rojo Abstract #: 1029 Presentation Title: Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2- metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial. Date & Time: June 2, 2024; 9:00 AM – 12:00 PM CDT Location: Hall A #ASCO24 #Breastcancer #metastaticbreastcancer #HER2 #FLIPPER #hormonereceptor #CDK4/6 #OncologyInnovation #cancerbiomarkers #liquidbiopsy #MeetUsThere #TherapyMonitoring #SysmexInnovations #CancerResearch #cancerdrugdevelopment #cookiemonster #GEICAM
-
-
🚨Highlights from ESMO 2024! Dr Pieterjan Vanclooster, resident in medical oncology at University Hospital Antwerp, shares key findings from the proffered paper session: - Phase 3 NPC Trial: A new treatment approach reduces severe toxicity in nasopharyngeal carcinoma. - TACTI-003 Trial: Combination immunotherapy shows promise in recurrent head and neck cancer. - Safety Profile: No new safety signals observed with combination therapy. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #HeadAndNeckCancer #Oncology #CancerResearch #ClinicalTrials
-
Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in Uveal Melanoma 📢 @myESMO #MedicalOncology #CancerNews #Oncology #Cancer
Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in Uveal Melanoma
esmo.org
